Newsletter | December 9, 2025

12.09.25 -- Scalable, High-Efficiency CRISPR: The Next Generation Of Non-Viral T-Cell Gene Editing

 

An Introduction To Transfection Methods

 

This technical guide provides information on the most common methods of gene delivery and compares them to Nucleofection. Delve into their advantages, disadvantages, and ideal applications.

 

Enhancing CRISPR Knock-In And Knock-Out With The 4D-Nucleofector® LV PRO

Achieve scalable, non-viral CRISPR delivery for T cells. The next-generation electroporation platform provides robust, efficient gene editing in large-scale volumes. Discover the data supporting this non-viral method for reliable manufacturing of gene-edited cells.

 

Non-Viral And Large-Scale Delivery Of Gene Editing Tools For T-Cell Manufacturing

Explore an advanced electroporation platform that enables reliable, large-scale, non-viral delivery of complex gene editing tools like CRISPR/Cas9 for T-cell manufacturing. Optimize your workflow for up to 1 billion cells.

 

VIDEO FEATURE

A Technology Introduction: Non-Viral Delivery Of Complex Cargos

Future cell therapies rely on scalable, high-efficiency gene editing. We operate at the forefront of emerging technologies to help pioneer our customers’ breakthrough medicines. Learn how next-generation electroporation technology enables the high-performance modification of T cells needed for commercial manufacturing success.

 

SOLUTIONS

Improve Viral Titers In Your AAV Program

The TheraPEAK 293-GT® Media System is a flexible, drop-in-ready solution designed to support high-yield AAV manufacturing in suspension HEK293 cells across transfection reagents, cell lines, and plasmid backbones.

• Request Information